Vanda Pinto, PhD, science writer —

Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.

Articles by Vanda Pinto

Umbilical Cord Stem Cells Hold Potential in PF Treatment

Small extracellular vesicles (EVs) released from umbilical cord stem cells seem to carry molecules that can inhibit the TGF-beta signaling pathway and reduce tissue damage in the lungs of mice with pulmonary fibrosis (PF), a study shows. The findings support further research on stem cell-derived EVs as a potential…

IPF Worsens Prognosis in Lung Cancer Patients

Idiopathic pulmonary fibrosis (IPF) is associated with poorer prognosis in patients with lung cancer, a study shows. People with lung cancer showed a higher risk of dying if IPF was present. The findings also suggest that lung cancer treatments, such as chemotherapy, can contribute to poor clinical outcomes by…

PulmoSIM Launched to Repurpose Medications for Rare Lung Conditions

VeriSIM Life has launched a pharmaceutical subsidiary called PulmoSIM Therapeutics (PulmoSIM) to search for new treatments for rare lung diseases. Using artificial intelligence, PulmoSIM’s goal is to assess which therapies previously approved by the U.S. Food and Drug Administration for certain conditions can be effective for the treatment of…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums